Bayer's asundexian wins China approval for stroke risk reduction

PUBT · 2d ago
Bayer's asundexian wins China approval for stroke risk reduction
  • Bayer’s asundexian received approval in China for stroke risk reduction.
  • The drug is the first Factor XIa inhibitor approved in China, following priority review.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.